dc.creatorErrecalde, Carlos A.
dc.creatorPrieto, Guillermo F.
dc.creatorLüders Post, Carlos
dc.date2018
dc.date2021-04-30T17:07:24Z
dc.date2021-04-30T17:07:24Z
dc.date.accessioned2021-06-14T22:08:05Z
dc.date.available2021-06-14T22:08:05Z
dc.identifierREVISTA DE INVESTIGACIONES VETERINARIAS DEL PERU,Vol.29,479-485,2018
dc.identifierhttp://repositoriodigital.uct.cl/handle/10925/4181
dc.identifier10.15381/rivep.v29i2.14490
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/3301296
dc.descriptionPharmacokinetic parameters of danofloxacin at 2.5% were determined after intravenous and intramuscular application in adult goat females. Plasma levels were quantified by HPLC with fluorescence detector set at 295 nm excitation and 490 nm emission using mobile phase composed of water, acetonitrile and triethylamine (79:19:1 v/v/v) adjusted to pH 3.0. In each route of application, using plasma concentrations versus time data in each animal, pharmacokinetic parameters were determined with PK Solution 2.0 software. Quantification limit of the assay was 0.0048 mu g/ml. The kinetic profile exhibited by danofloxacin in goats was similar to that of fluoroquinolones in domestic animals The intramuscular application provides rapid absorption, produces a Cmax of 0.36 +/- 0.13 mu g/ml at 55.1 +/- 13.8 minutes, and exhibits wide distribution in the organism and bioavailability (F) of 109.7 +/- 19.8%. Danofloxacin showed a slight permanence in the organism, according to the values obtained in t1/2 beta = 4.35 hours (EV), 4.32 hours (IM) and in the TMR = 5.9 hours (EV), 6.7 hours (IM). Intramuscular and intravenous application are comparable, but rational use requires dosage adjustment to ensure clinical and therapeutic success, because plasma Cmax/ MIC90 and ABC/MIC90 ratios of 9 and 41, respectively in relation to MIC90 of M. haemolytica, are insufficient to ensure clinical-microbiological efficacy.
dc.languagees
dc.publisherUNIV NACIONAL MAYOR SAN MARCOS
dc.sourceREVISTA DE INVESTIGACIONES VETERINARIAS DEL PERU
dc.subjectfluoroquinolones
dc.subjectgoat
dc.subjectpharmacokinetic
dc.titlePLASMA DISPOSITION OF DANOFLOXACIN 2.5% IN GOATS
dc.typeArticle


Este ítem pertenece a la siguiente institución